ATE366115T1 - Inotropische und diuretische effekte von exendin und glp-1 - Google Patents
Inotropische und diuretische effekte von exendin und glp-1Info
- Publication number
- ATE366115T1 ATE366115T1 AT99906762T AT99906762T ATE366115T1 AT E366115 T1 ATE366115 T1 AT E366115T1 AT 99906762 T AT99906762 T AT 99906762T AT 99906762 T AT99906762 T AT 99906762T AT E366115 T1 ATE366115 T1 AT E366115T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- exendin
- glp
- disclosed
- inotropic
- Prior art date
Links
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title abstract 3
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title abstract 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 3
- 230000000297 inotrophic effect Effects 0.000 title abstract 2
- 230000001882 diuretic effect Effects 0.000 title 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 2
- 206010019280 Heart failures Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 abstract 2
- 230000002485 urinary effect Effects 0.000 abstract 2
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010020919 Hypervolaemia Diseases 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 206010029164 Nephrotic syndrome Diseases 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- 206010037423 Pulmonary oedema Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000029142 excretion Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- 239000011591 potassium Substances 0.000 abstract 1
- 208000005333 pulmonary edema Diseases 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7512298P | 1998-02-13 | 1998-02-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE366115T1 true ATE366115T1 (de) | 2007-07-15 |
Family
ID=22123696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99906762T ATE366115T1 (de) | 1998-02-13 | 1999-02-05 | Inotropische und diuretische effekte von exendin und glp-1 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1054594B1 (de) |
| JP (1) | JP4677095B2 (de) |
| AT (1) | ATE366115T1 (de) |
| AU (1) | AU759058C (de) |
| CA (1) | CA2320371C (de) |
| DE (1) | DE69936446T2 (de) |
| ES (1) | ES2291017T3 (de) |
| WO (1) | WO1999040788A1 (de) |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US6852690B1 (en) | 1995-08-22 | 2005-02-08 | Amylin Pharmaceuticals, Inc. | Method and composition for enhanced parenteral nutrition |
| NZ512663A (en) | 1999-01-14 | 2004-05-28 | Amylin Pharmaceuticals Inc | Novel exendin agonist formulations and methods of administration thereof |
| DK1143989T3 (da) | 1999-01-14 | 2007-04-16 | Amylin Pharmaceuticals Inc | Exendiner til glucagonundertrykkelse |
| US7399489B2 (en) | 1999-01-14 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Exendin analog formulations |
| US6506724B1 (en) | 1999-06-01 | 2003-01-14 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
| EP1076066A1 (de) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptide zur Senkung des Blutglukosespiegels |
| US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
| EP2206720A1 (de) | 2000-04-12 | 2010-07-14 | Human Genome Sciences, Inc. | Albuminfusionsproteine |
| WO2002034285A2 (en) * | 2000-10-20 | 2002-05-02 | Coolidge Thomas R | Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide |
| BR0116024A (pt) | 2000-12-07 | 2005-12-13 | Lilly Co Eli | Proteìna de fusão heteróloga e uso da mesma |
| EP1411968B1 (de) | 2001-07-31 | 2008-09-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Glp 1 exendin 4 peptidanaloga und deren verwendungen |
| CA2463908A1 (en) * | 2001-10-18 | 2003-04-24 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| EP2261250B1 (de) | 2001-12-21 | 2015-07-01 | Human Genome Sciences, Inc. | GCSF-Albumin Fusionsproteine |
| CN1332711C (zh) | 2002-02-20 | 2007-08-22 | 埃米球科技有限公司 | 施用glp－1分子的方法 |
| AU2003268621B2 (en) | 2002-10-02 | 2009-01-15 | Zealand Pharma A/S | Stabilized exendin-4 compounds |
| AU2003297356A1 (en) * | 2002-12-17 | 2004-07-14 | Amylin Pharmaceuticals, Inc. | Prevention and treatment of cardiac arrhythmias |
| US7790681B2 (en) | 2002-12-17 | 2010-09-07 | Amylin Pharmaceuticals, Inc. | Treatment of cardiac arrhythmias with GLP-1 receptor ligands |
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| CA2513213C (en) | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| AU2004240630B2 (en) | 2003-05-15 | 2010-10-07 | Trustees Of Tufts College | Stable analogs of peptide and polypeptide therapeutics |
| EP1631308B1 (de) * | 2003-05-30 | 2013-07-31 | Amylin Pharmaceuticals, LLC | Neue verfahren und zusammensetzungen für die verbesserte transmukosale abgabe von peptiden und proteinen |
| EP1581246B1 (de) * | 2003-12-17 | 2013-01-16 | Amylin Pharmaceuticals, LLC | Zusammensetzungen zur behandlung und prevention von nephropathie |
| JP2006514649A (ja) * | 2003-12-17 | 2006-05-11 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 腎症の治療および予防のための組成物 |
| US20060286129A1 (en) | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
| CA2589800A1 (en) | 2004-12-02 | 2006-06-08 | Domantis Limited | Bispecific domain antibodies targeting serum albumin and glp-1 or pyy |
| WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| WO2006110887A2 (en) | 2005-04-11 | 2006-10-19 | Amylin Pharmaceuticals, Inc | Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling |
| AU2007267833B2 (en) * | 2006-05-26 | 2012-07-26 | Amylin Pharmaceuticals, Llc | Composition and methods for treatment of congestive heart failure |
| MX2008014870A (es) | 2006-05-30 | 2009-02-12 | Intarcia Therapeutics Inc | Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas. |
| EP2049081B1 (de) | 2006-08-09 | 2012-11-14 | Intarcia Therapeutics, Inc. | Osmotische freisetzungssysteme und kolbenanordnungen |
| RU2413528C2 (ru) | 2007-01-18 | 2011-03-10 | Открытое Акционерное Общество "Валента Фармацевтика" | Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения |
| HRP20130259T1 (hr) | 2007-04-23 | 2013-04-30 | Intarcia Therapeutics, Inc. | Suspenzijske formulacije inzulinotropnih peptida i njihove uporabe |
| EP2164519A2 (de) | 2007-06-08 | 2010-03-24 | Ascendis Pharma AS | Langwirkende polymer-prodrugs von exendin |
| DK2240155T3 (da) | 2008-02-13 | 2012-09-17 | Intarcia Therapeutics Inc | Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler |
| KR20100132535A (ko) | 2008-03-31 | 2010-12-17 | 글락소 그룹 리미티드 | 약물 융합체 및 컨주게이트 |
| EP2303313B1 (de) | 2008-05-21 | 2015-10-28 | Amylin Pharmaceuticals, LLC | Exendine zur senkung der cholesterin- und triglyceridwerte |
| CN102256618A (zh) | 2008-10-17 | 2011-11-23 | 赛诺菲-安万特德国有限公司 | 胰岛素和glp-1激动剂的组合 |
| EP2411054A2 (de) | 2009-03-27 | 2012-02-01 | Glaxo Group Limited | Arzneifusionen und konjugate |
| EP2435061A4 (de) | 2009-05-28 | 2013-03-27 | Amylin Pharmaceuticals Inc | Schlaffördernde glp-1-rezeptor-agonistenverbindungen |
| PL2451437T3 (pl) | 2009-07-06 | 2017-05-31 | Sanofi-Aventis Deutschland Gmbh | Wodne preparaty insuliny zawierające metioninę |
| AU2010277559B2 (en) | 2009-07-31 | 2016-08-11 | Sanofi-Aventis Deutschland Gmbh | Prodrugs comprising an insulin linker conjugate |
| PL2459171T3 (pl) | 2009-07-31 | 2017-11-30 | Sanofi-Aventis Deutschland Gmbh | Kompozycja insuliny o długim działaniu |
| SMT201700583T1 (it) | 2009-09-28 | 2018-01-11 | Intarcia Therapeutics Inc | Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario |
| MX2012003939A (es) | 2009-09-30 | 2012-07-30 | Glaxo Group Ltd | Fusiones y conjugados de farmaco. |
| NZ599847A (en) | 2009-11-13 | 2013-09-27 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist and methionine |
| TR201809460T4 (tr) | 2009-11-13 | 2018-07-23 | Sanofi Aventis Deutschland | Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim. |
| BR112012018104A2 (pt) * | 2010-01-20 | 2017-10-17 | Zeland Pharma As | tratamento de doenças cardíacas |
| RU2422461C1 (ru) * | 2010-02-09 | 2011-06-27 | Федеральное государственное образовательное учреждение высшего профессионального образования Санкт-Петербургский государственный университет | Аналоги эксенатида |
| EA023925B1 (ru) | 2010-04-27 | 2016-07-29 | Зилэнд Фарма А/С | Пептидные конъюгаты агонистов рецептора glp-1 и их применение |
| WO2012028172A1 (en) | 2010-08-30 | 2012-03-08 | Sanofi-Aventis Deutschland Gmbh | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
| EP2438930A1 (de) | 2010-09-17 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Prodrug mit einem exendinbindenden Konjugat |
| WO2012050923A2 (en) | 2010-09-28 | 2012-04-19 | Amylin Pharmaceuticals, Inc. | Engineered polypeptides having enhanced duration of action |
| WO2012052177A1 (en) * | 2010-10-20 | 2012-04-26 | Universität Heidelberg | Short peptides for enhancing muscle function |
| JP2014504588A (ja) | 2010-12-22 | 2014-02-24 | アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | 膵島細胞移植のためのｇｌｐ−１受容体アゴニスト |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| WO2012136790A1 (en) | 2011-04-07 | 2012-10-11 | Glaxo Group Limited | Compositions comprising fusion proteins or conjugates with an improved half -life |
| WO2012136792A2 (en) | 2011-04-07 | 2012-10-11 | Glaxo Group Limited | Cck compositions |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| JP2014521594A (ja) | 2011-05-25 | 2014-08-28 | アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | 長持続期間デュアルホルモンコンジュゲート |
| JP6006309B2 (ja) | 2011-07-08 | 2016-10-12 | アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド |
| AR087693A1 (es) | 2011-08-29 | 2014-04-09 | Sanofi Aventis Deutschland | Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2 |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| MX2014005351A (es) | 2011-11-03 | 2014-05-28 | Zealand Pharma As | Conjugados de gastrina peptidicos de agonistas de receptor glp-1. |
| JP2015523332A (ja) | 2012-05-16 | 2015-08-13 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | 経口投与のためのポリペプチド搭載ｐｏｃａナノ粒子 |
| WO2013170636A1 (zh) | 2012-05-18 | 2013-11-21 | 爱德迪安（北京）生物技术有限公司 | 用于糖尿病治疗的蛋白、蛋白缀合物及其应用 |
| AU2013295035B2 (en) | 2012-07-23 | 2017-08-03 | Zealand Pharma A/S | Glucagon analogues |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
| SG11201508469YA (en) | 2013-05-02 | 2015-11-27 | Glaxosmithkline Ip Dev Ltd | Therapeutic peptides |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| WO2015055801A1 (en) | 2013-10-17 | 2015-04-23 | Zealand Pharma A/S | Acylated glucagon analogues |
| MX2016005556A (es) | 2013-11-06 | 2016-07-15 | Zealand Pharma As | Compuestos agonistas duales de gip-glp-1 y procedimientos. |
| AU2014345570B2 (en) | 2013-11-06 | 2019-01-24 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
| CN112043835B (zh) | 2013-12-06 | 2022-10-21 | 韩捷 | 用于含氮和羟基的药物的生物可逆引入基团 |
| CN105960249B (zh) | 2014-01-09 | 2021-03-16 | 赛诺菲 | 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂 |
| US9895423B2 (en) | 2014-01-09 | 2018-02-20 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
| JP6723921B2 (ja) | 2014-01-09 | 2020-07-15 | サノフイＳａｎｏｆｉ | インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤 |
| RU2573933C1 (ru) | 2014-08-21 | 2016-01-27 | Дафот Энтерпрайсис Лимитед | Пептид для лечения сахарного диабета 2-го типа и его осложнений |
| GB201415598D0 (en) | 2014-09-03 | 2014-10-15 | Univ Birmingham | Elavated Itercranial Pressure Treatment |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| US10253078B2 (en) | 2014-10-29 | 2019-04-09 | Zealand Pharma A/S | GIP agonist compounds and methods |
| PE20171622A1 (es) | 2014-12-12 | 2017-11-02 | Sanofi Aventis Deutschland | Formulacion de relacion fija de insulina glargina/lixisenatida |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| US10336802B2 (en) | 2015-04-16 | 2019-07-02 | Zealand Pharma A/S | Acylated glucagon analogue |
| US10925639B2 (en) | 2015-06-03 | 2021-02-23 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
| KR102844773B1 (ko) | 2015-12-23 | 2025-08-13 | 암젠 인크 | 위 억제 펩티드 수용체 (gipr)에 대한 결합 단백질을 glp-1 효능제와 조합하여 사용하여 대사 장애를 치료하거나 개선시키는 방법 |
| RU2760007C2 (ru) | 2016-05-16 | 2021-11-22 | Интарсия Терапьютикс, Инк. | Полипептиды, селективные к рецепторам глюкагона, и способы их применения |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| US11285180B2 (en) | 2016-12-06 | 2022-03-29 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods of enhancing the potency of incretin-based drugs in subjects in need thereof |
| AU2017371516C1 (en) | 2016-12-09 | 2021-09-02 | Zealand Pharma A/S | Acylated GLP-1/GLP-2 dual agonists |
| CN110225762A (zh) | 2017-01-03 | 2019-09-10 | 因塔西亚制药公司 | 包括glp-1受体激动剂的连续施用和药物的共同施用的方法 |
| BR112019014588A2 (pt) | 2017-01-17 | 2020-02-18 | Amgen Inc. | Método de tratamento ou amenização de distúrbios metabólicos usando agonistas do receptor de glp-1 conjugados a antagonistas para receptor do peptídeo inibidor gástrico (gipr) |
| CN110831969B (zh) | 2017-06-20 | 2024-06-21 | 安进公司 | 使用抑胃肽受体（gipr）结合蛋白与glp-1激动剂的组合治疗或改善代谢障碍的方法 |
| MX2019015544A (es) | 2017-06-21 | 2020-07-28 | Amgen Inc | Metodo para tratar o mejorar trastornos metabolicos con proteinas de fusion de agonistas del receptor de glp-1/proteinas de union antagonistas para el receptor peptidico inhibidor gastrico (gipr). |
| HRP20240485T1 (hr) | 2017-08-24 | 2024-07-05 | Novo Nordisk A/S | Pripravci glp-1 i njihova upotreba |
| EP3934679A1 (de) | 2019-03-08 | 2022-01-12 | Amgen Inc. | Kombinationstherapie mit wachstumsdifferenzierungsfaktor 15 |
| PE20230819A1 (es) | 2020-02-18 | 2023-05-19 | Novo Nordisk As | Composiciones y usos de glp-1 |
| WO2024123812A1 (en) | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Fusion proteins for the treatment of cardiometabolic diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5424286A (en) * | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| WO1998005351A1 (en) * | 1996-08-08 | 1998-02-12 | Amylin Pharmaceuticals, Inc. | Methods for regulating gastrointestinal motility |
| CA2299425A1 (en) * | 1997-08-08 | 1999-02-18 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
-
1999
- 1999-02-05 AT AT99906762T patent/ATE366115T1/de not_active IP Right Cessation
- 1999-02-05 AU AU26596/99A patent/AU759058C/en not_active Ceased
- 1999-02-05 ES ES99906762T patent/ES2291017T3/es not_active Expired - Lifetime
- 1999-02-05 EP EP99906762A patent/EP1054594B1/de not_active Expired - Lifetime
- 1999-02-05 DE DE69936446T patent/DE69936446T2/de not_active Expired - Lifetime
- 1999-02-05 JP JP2000531064A patent/JP4677095B2/ja not_active Expired - Fee Related
- 1999-02-05 CA CA2320371A patent/CA2320371C/en not_active Expired - Fee Related
- 1999-02-05 WO PCT/US1999/002554 patent/WO1999040788A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE69936446T2 (de) | 2008-03-06 |
| JP4677095B2 (ja) | 2011-04-27 |
| EP1054594A1 (de) | 2000-11-29 |
| ES2291017T3 (es) | 2008-02-16 |
| DE69936446D1 (de) | 2007-08-16 |
| AU2659699A (en) | 1999-08-30 |
| AU759058B2 (en) | 2003-04-03 |
| WO1999040788A1 (en) | 1999-08-19 |
| EP1054594A4 (de) | 2002-04-17 |
| CA2320371A1 (en) | 1999-08-19 |
| JP2002509078A (ja) | 2002-03-26 |
| AU759058C (en) | 2005-09-15 |
| EP1054594B1 (de) | 2007-07-04 |
| CA2320371C (en) | 2012-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE366115T1 (de) | Inotropische und diuretische effekte von exendin und glp-1 | |
| Beyer et al. | Renotropic characteristics of ethacrynic acid: a phenoxyacetic saluretic-diuretic agent | |
| EA200701364A1 (ru) | Композиции слитых белков-аналогов glp-1 | |
| ATE444306T1 (de) | Fgf-21-fusionsproteine | |
| NO20055402L (no) | Legemiddelkonjugatblanding | |
| BR0209689A (pt) | Uso de fragmento de hmg como agente anti-inflamatório | |
| TR200003149T2 (tr) | Mide asidi salgılanmasını önleyen imidazo piridin türevleri. | |
| Romero et al. | Selenium cytotoxicity in Tetrahymena thermophila: New clues about its biological effects and cellular resistance mechanisms | |
| DE10346913A1 (de) | Acylhydrazonderivate | |
| MA33811B1 (fr) | Composés et méthodes utilisés pour la modulation kinases et indications à cet effet | |
| WO2003105800A3 (de) | Filmförmige mucoadhäsive darreichungsformen zur verabreichung von cannabis-wirkstoffen | |
| WO2000066138A3 (en) | Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue | |
| BR0008664A (pt) | Métodos para o tratamento de, e para prevenir oucontrolar, distúrbios gastrointestinais,disfunção da motilidade gastrointestinal, emese, edoença de refluxo gastro-esofagiano em umpaciente, e, composição farmacêutica | |
| BR0008687A (pt) | Métodos para o tratamento de, e para prevenir ou controlar, distúrbios gastrointestinais, disfunção da motilidade gastrointestinal, emese, e doença de refluxo gastro-esofageano em um paciente, e, composição farmacêutica | |
| DK1631312T3 (da) | Sammensætning og fremstillingsmåde til behandling af inflammatorisk tarmsygdom | |
| Kiela et al. | Ion transport in the intestine | |
| DK1213972T3 (da) | Komposition omfattende en alfa-amylase-inhibitor og mindst en fysiologisk acceptabel forbindelse, der kan nedsætte absorptionen af "hurtigere sukkere" i tarmen | |
| DK1735296T3 (da) | Materialer og fremgangsmåder til behandling af koagulationslidelser | |
| DE69931279D1 (de) | Methode und zusammensetzungen zum vermindern des cholesterolspiegels im plasma | |
| Crowe et al. | Presentation of hepatitis C in a unique uniform cohort 17 years from inoculation | |
| Bistrup et al. | Reduced activity of 11β‐hydroxysteroid dehydrogenase type 2 is not responsible for sodium retention in nephrotic rats | |
| DK1058544T3 (da) | Inhibition af TNF-aktivitet med præparater, der omfatter heparin og oplöselige TNF-receptorer | |
| He et al. | Sustained endoplasmic reticulum stress inhibits hepatocyte proliferation via downregulation of c-Met expression | |
| Lin et al. | The dramatic effect of intravenous glycyrrhizin on acute‐on‐chronic hepatic failure in chronic hepatitis B patients without liver cirrhosis | |
| GB534913A (en) | Improvements in or relating to collapsible bridges |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |